Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation Journal Article


Authors: Pencheva, N.; Buss, C. G.; Posada, J.; Merghoub, T.; Tavazoie, S. F.
Article Title: Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation
Abstract: Melanoma metastasis is a devastating outcome lacking an effective preventative therapeutic. We provide pharmacologic, molecular, and genetic evidence establishing the liver-X nuclear hormone receptor (LXR) as a therapeutic target in melanoma. Oral administration of multiple LXR agonists suppressed melanoma invasion, angiogenesis, tumor progression, and metastasis. Molecular and genetic experiments revealed these effects to be mediated by LXRβ, which elicits these outcomes through transcriptional induction of tumoral and stromal apolipoprotein-E (ApoE). LXRβ agonism robustly suppressed tumor growth and metastasis across a diverse mutational spectrum of melanoma lines. LXRβ targeting significantly prolonged animal survival, suppressed the progression of established metastases, and inhibited brain metastatic colonization. Importantly, LXRβ activation displayed melanoma-suppressive cooperativity with the frontline regimens dacarbazine, B-Raf inhibition, and the anti-CTLA-4 antibody and robustly inhibited melanomas that had acquired resistance to B-Raf inhibition or dacarbazine. We present a promising therapeutic approach that uniquely acts by transcriptionally activating a metastasis suppressor gene. © 2014 Elsevier Inc.
Keywords: cancer survival; controlled study; protein expression; nonhuman; mouse; phenotype; animal tissue; cytotoxic t lymphocyte antigen 4 antibody; dacarbazine; low drug dose; melanoma; enzyme inhibition; animal experiment; animal model; genetic transcription; tumor suppressor gene; lung metastasis; brain metastasis; melanoma cell; tumor growth; hormone receptor; b raf kinase; metastatic melanoma; apolipoprotein e; vemurafenib; priority journal; article; 3 [3 [[2 chloro 3 (trifluoromethyl)benzyl](2 diphenylethyl)amino]propoxy]phenylacetic acid; liver x receptor; n (2,2,2 trifluoroethyl) n [4 (2,2,2 trifluoro 1 hydroxy 1 trifluoromethylethyl)phenyl]benzenesulfonamide
Journal Title: Cell
Volume: 156
Issue: 5
ISSN: 0092-8674
Publisher: Cell Press  
Date Published: 2014-02-27
Start Page: 986
End Page: 1001
Language: English
DOI: 10.1016/j.cell.2014.01.038
PROVIDER: scopus
PUBMED: 24581497
DOI/URL:
Notes: Export Date: 2 April 2014 -- CODEN: CELLB -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Taha Merghoub
    364 Merghoub